ImageneBio (IMA) Cash & Current Investments (2020 - 2025)

ImageneBio has reported Cash & Current Investments for 6 years, with the latest figure at $135.3 million in Q4 2025.

• Quarterly Cash & Current Investments rose 39.38% year-over-year to $135.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $135.3 million (up 39.38% YoY) and the FY2025 annual result came in at $135.3 million, up 39.38% from the prior year.
• Cash & Current Investments slipped to $135.3 million in Q4 2025 per IMA's latest filing, from $142.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $281.0 million in Q1 2021 and troughed at $95.6 million in Q2 2025.
• A 5-year average of $172.6 million and a median of $157.3 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2024: Cash & Current Investments jumped 340.21% in 2021, then tumbled 44.66% in 2024.
• Over 5 years, Cash & Current Investments stood at $232.2 million in 2021, then plunged by 32.41% to $156.9 million in 2022, then climbed by 11.8% to $175.5 million in 2023, then sank by 44.66% to $97.1 million in 2024, then jumped by 39.38% to $135.3 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $135.3 million, $142.6 million, and $95.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.